跳到正文
原文
MedPage Today·· 2026-10-08精选AI 评分71

FDA 批准 Rhapsido 扩展用于症状性皮肤划痕症治疗

FDA Expands Indication for Urticaria Drug to Treat Symptomatic Dermographism

AI 导读

诺华宣布 FDA 将 BTK 抑制剂 remibrutinib(商品名 Rhapsido)适应症扩展至用于成人症状性皮肤划痕症的一线治疗,适用于 H1 抗组胺药控制不佳的患者。

推荐理由

原文明确给出了 FDA 批准的适应症扩展与 RemIND 试验关键疗效数据,读者可据此了解该药的适用范围与证据水平。

正文 · 原文

— Twice as many complete responses with remibrutinib in a placebo-controlled trial

October 7, 2026 • 2 min read

The FDA expanded the indication of the Bruton's tyrosine kinase (BTK) inhibitor remibrutinib (Rhapsido) to treat symptomatic dermographism, the most common form of chronic inducible urticaria, Novartis announced Thursday.

The approval allows use of the oral agent as initial treatment for adults with symptomatic dermographism inadequately controlled by H1 antihistamines. Remibrutinib becomes the first prescription drug approved for both chronic spontaneous urticaria and symptomatic dermographism, collectively occurring in more than 90% of patients with chronic hives.

"SD [symptomatic dermographism] is a chronic, debilitating condition with historically limited treatment options," said Giselle Mosnaim, MD, of Endeavor Health and the University of Chicago Pritzker School of Medicine, in the company press release. "Remibrutinib offers, for the first time, an approach to treatment specifically for SD patients who remain inadequately controlled by H1 antihistamines alone, representing a meaningful step forward for this population."

Principal support for the approval came from the symptomatic dermographism cohort of the phase III RemIND trial of patients with chronic inducible urticaria that remained symptomatic despite treatment with second-generation H1 antihistamines. Participants who received the BTK inhibitor had higher rates of complete response compared with the placebo group as determined by the Total Fric Score. At 12 weeks, more than twice as many participants in the remibrutinib group met criteria for complete response (29.3% vs 14.0%, P=0.0229). Responses were observed as early as 2 weeks after starting remibrutinib.

Remibrutinib had a consistent safety profile in clinical trials with follow-up to 24 weeks. The most common adverse events (≥3% of patients) were nasal congestion, sore throat, nasopharyngitis, bleeding, headache, nausea, and abdominal pain.

来源:MedPage Today · medpagetoday.com